Pharmabiz15h
March Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma
Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
In the Opportunity Research report, analyst Rob Goldman reviews clinical and preclinical data on OKYO's lead candidate, the Company's inherent first-mover opportunities in the industry, upcoming ...
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –– Achieved Statistical Significance with Up to 48% Slowing of Clinical ...
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™
Zevra to receive a 2025 New Treatment Award for MIPLYFFA™ at the 21st Annual WORLDSymposiumEight abstracts discussing data and clinical ...
NBC on MSN1h
Shameless Star Justin Chatwin Had a Pivotal Law & Order Role in a Heartbreaking Episode
Attorney Nolan Price found himself at odds with his brother, played by Chatwin, as the siblings were forced to make a painful ...
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline
Moleculin Biotech Inc (NASDAQ:MBRX) stock has reached a 52-week low, trading at $1.46, down 85% from its 52-week high of $10.35. According to InvestingPro analysis, the company maintains a favorable ...
JD Supra8h
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...
Notice of Extraordinary General Meeting in Ascelia Pharma AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / January ...
Effective Pharma Marketing Authorisation Application Training Course (ONLINE EVENT: February 5-6, 2025)
The "Clinical Overview and Clinical Summary: Creating Effective Marketing Authorisation Application Training Course" conference has been added to ResearchAndMarkets.com's offering. The Common ...
Healthcare Contract Research Organization Market Size to Surpass USD 93.23 Billion by 2032, Growing at a 7.10% CAGR - SNS Insider
Global Healthcare CRO Market Growth is Driven by Rising Investments in R&D, Regulatory Complexity, and Adoption of Decentralized Clinical Trials.Pune, Jan. 30, 2025 (GLOBE NEWSWIRE) -- “According to ...